Continual planning and evaluation have been key to the development and sustained excellence of the research infrastructure at the Markey Cancer Center (MCC). Planning and evaluation activities are accomplished through the internal and external advisory boards, councils, and committees that provide the Director and Senior Leadership ongoing guidance and support. The MCC External Advisory Board (EAB) is the primary external mechanism for review and advice on the MCC's progress in basic and translational research and community research. Internal mechanisms include the advice and support of MCC's Senior Leaders, who formally comprise the MCC Director's Council;the MCC Scientific Advisory Panel;and an Internal Advisory Board (lAB) comprised of deans, center directors, and department chairs at the University of Kentucky. Other planning and evaluation efforts occur at the program and shared resource levels. Shortly after joining the MCC in 2009, Dr. Evers and the Senior Leadership developed a strategic plan for the MCC, which has served as a road map to guide the development of scientific research programs and initiatives, the reorganization of shared resources required to facilitate and achieve the scientific goals, and strategic recruitments of basic and translational scientists who will synergize and further strengthen ongoing research efforts over a five-year period. The strategic plan outlines directions for research to be developed, the need for expanded services within existing shared resources, and organizational strategies to improve collaboration and interdisciplinary interactions. This strategic plan is regularly reviewed for progress and revised. The most recent review and revision process was conducted in 2012 to reflect the tremendous progress that has occurred over three years and to redefine the strategic goals for the next five years based on the stronger foundations that are now in place.
The MCC has set up an ongoing and continual planning and evaluation process which has been instrumental in the dramatic growth in translational and interdisciplinary research, collaborative publications and interactions, and enrollment in clinical trials.
|Wei, Xiaowei; Xu, Yong; Xu, Fang Fang et al. (2017) RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells. Cancer Res 77:1345-1356|
|Cui, Jiajun; Xu, Wenhua; Chen, Jian et al. (2017) M2 polarization of macrophages facilitates arsenic-induced cell transformation of lung epithelial cells. Oncotarget 8:21398-21409|
|Wu, Yadi; Wang, Yu; Lin, Yiwei et al. (2017) Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation. Nat Commun 8:14228|
|Wise, James T F; Wang, Lei; Zhang, Zhuo et al. (2017) The 9th Conference on Metal Toxicity and Carcinogenesis: The conference overview. Toxicol Appl Pharmacol 331:1-5|
|Carpenter, Brittany L; Liu, Jinpeng; Qi, Lei et al. (2017) Integrin ?6?4 Upregulates Amphiregulin and Epiregulin through Base Excision Repair-Mediated DNA Demethylation and Promotes Genome-wide DNA Hypomethylation. Sci Rep 7:6174|
|Jarrett, Stuart G; D'Orazio, John A (2017) Hormonal Regulation of the Repair of UV Photoproducts in Melanocytes by the Melanocortin Signaling Axis. Photochem Photobiol 93:245-258|
|Li, Liqing; Li, Xiang; Qi, Lei et al. (2017) The role of talin2 in breast cancer tumorigenesis and metastasis. Oncotarget 8:106876-106887|
|Kenlan, Dasha E; Rychahou, Piotr; Sviripa, Vitaliy M et al. (2017) Fluorinated N,N'-Diarylureas As Novel Therapeutic Agents Against Cancer Stem Cells. Mol Cancer Ther 16:831-837|
|Son, Young-Ok; Pratheeshkumar, Poyil; Divya, Sasidharan Padmaja et al. (2017) Nuclear factor erythroid 2-related factor 2 enhances carcinogenesis by suppressing apoptosis and promoting autophagy in nickel-transformed cells. J Biol Chem 292:8315-8330|
|Arnold, Susanne M; Chansky, Kari; Leggas, Markos et al. (2017) Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553). Invest New Drugs 35:608-615|
Showing the most recent 10 out of 281 publications